Loading…
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $84M | $-267M | $-264M | $-263M | -49.1% | 54.0% | 36.6% |
| 2024 | $55M | $-197M | $-194M | $-182M | -36.7% | -29.1% | 34.5% |
| 2023 | $77M | $-141M | $-144M | $-90M | -71.8% | 99.3% | -20.2% |
| 2022 | $39M | $-173M | $-180M | $-172M | -59.4% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 38.63 | 76.99 | 54.55 | 83.98 |
| Operating Revenue | - | 38.63 | 76.99 | 54.55 | 83.98 |
| Operating Expense | - | 222.49 | 232.05 | 267.58 | 369.65 |
| Research And Development | - | 184.50 | 189.15 | 221.63 | 316.90 |
| Selling General And Administration | - | 38 | 42.90 | 45.94 | 52.74 |
| Total Expenses | - | 222.49 | 232.05 | 267.58 | 369.65 |
| Operating Income | - | -183.87 | -155.06 | -213.03 | -285.67 |
| Total Operating Income As Reported | - | -183.87 | -155.06 | -213.03 | -285.67 |
| EBITDA | - | -173.06 | -141.41 | -196.60 | -266.81 |
| Normalized EBITDA | - | -173.06 | -141.41 | -196.60 | -266.81 |
| EBIT | - | -183.87 | -155.06 | -213.03 | -285.67 |
| Interest Income | - | 3.51 | 11.12 | 19.73 | 21.97 |
| Net Interest Income | - | 3.51 | 11.12 | 19.73 | 21.97 |
| Interest Income Non Operating | - | 3.51 | 11.12 | 19.73 | 21.97 |
| Net Non Operating Interest Income Expense | - | 3.51 | 11.12 | 19.73 | 21.97 |
| Pretax Income | - | -180.36 | -143.95 | -193.30 | -263.70 |
| Tax Provision | - | 0 | 0 | 0.27 | 0.76 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -180.36 | -143.95 | -193.57 | -264.46 |
| Net Income From Continuing And Discontinued Operation | - | -180.36 | -143.95 | -193.57 | -264.46 |
| Net Income From Continuing Operation Net Minority Interest | - | -180.36 | -143.95 | -193.57 | -264.46 |
| Net Income | - | -180.36 | -143.95 | -193.57 | -264.46 |
| Net Income Common Stockholders | - | -180.36 | -143.95 | -193.57 | -264.46 |
| Net Income Including Noncontrolling Interests | - | -180.36 | -143.95 | -193.57 | -264.46 |
| Normalized Income | - | -180.36 | -143.95 | -193.57 | -264.46 |
| Diluted NI Availto Com Stockholders | - | -180.36 | -143.95 | -193.57 | -264.46 |
| Basic Average Shares | - | 48.61 | 54.34 | 67.12 | 86.67 |
| Diluted Average Shares | - | 48.61 | 54.34 | 67.12 | 86.67 |
| Reconciled Depreciation | - | 10.81 | 13.65 | 16.43 | 18.86 |
| General And Administrative Expense | - | 38 | 42.90 | 45.94 | 52.74 |
| Other Gand A | - | 38 | 42.90 | 45.94 | 52.74 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Nurix Therapeutics, Inc.this co. | NRIX | $1.6B | - | 2.93 | -49.1% | - |
| Capricor Therapeutics, Inc. | CAPR | $1.6B | -15.41 | 5.29 | -34.4% | -13.44 |
| Tyra Biosciences, Inc. | TYRA | $1.6B | -13.48 | 6.24 | -46.3% | -11.68 |
| Syndax Pharmaceuticals, Inc. | SNDX | $1.6B | -5.59 | 24.71 | -441.6% | -7.18 |
| Amylyx Pharmaceuticals, Inc. | AMLX |
| - |
| - |
| - |
| - |
| - |
| - |
| $1.6B |
| -10.99 |
| 5.21 |
| -47.4% |
| -8.97 |
| agilon health, inc. | AGL | $1.6B | - | 12.54 | -308.8% | - |
| Sonida Senior Living, Inc. | SNDA | $1.6B | -22.19 | -142770.48 | 643445.5% | 96.78 |
| Vir Biotechnology, Inc. | VIR | $1.5B | - | 2.02 | -57.2% | - |
| ArriVent BioPharma, Inc. | AVBP | $1.5B | - | 5.02 | -54.1% | - |
| Peer Median | - | -13.48 | 5.25 | -50.8% | -8.97 | |